Phase 1/2a SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024…
Highlights AHI enters a second commercial agreement in the UAE.IntelliGen Founders have worked with, and within the Government, Healthcare needs…
JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) -- via IBN - BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on…
Charlotte, North Carolina--(Newsfile Corp. - August 10, 2023) - cbdMD, Inc. (NYSE American: YCBD) (NYSE American: YCBDpA), one of the…
CINCINNATI, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology and pharmaceutical…
Inovalon Converged Quality, Cloud Software Empowers More Than 80% of the Nation’s Clinical Outcomes Measurement AnalyticsBOWIE, Md., Aug. 10, 2023…
Ocean Biomedical will host a Research and Development Day, Live Q&A with Scientific Co-founders, Dr. Jack A. Elias, MD and Dr.…
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the…
Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call…
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the…